We undertook a post hoc, sponsor‐funded analysis of data from two recent clinical trials in CSU.
Remibrutinib numerically improved CSU symptoms at 12 h; meaningful effects persisted from Day‐2 through Week‐52.
Gordon Sussman, N. Chapman-Rothe, Tao Ding et al.· Clinical and Experimental Al...· 0 citations
The use of deucrictibant as potentially the first orally administered bradykinin B2 receptor antagonist for the treatment of attacks of bradykinin-mediated angioedema, including hereditary angioedema, is supported and may address an unmet need for options that are effective and well tolerated, with convenient administr...
Marc A. Riedl, P. Li, A. Adatia et al.· The Lancet· 1 citation
Chronic urticaria is a mast cell-driven inflammatory disease characterized by recurrent wheals, angioedema or both for more than 6 weeks, with substantial effects on sleep, quality of life, mental health and daily functioning. Type I autoallergic and type IIb autoimmune mechanisms represent major endotypes, but many pa...
A. Salman, M. Al-Ahmad, M. Al-Nesf et al.· Journal of the European Acad...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.